Benzonatate
Non-narcotic Antitussive — RESPIRATORY SYSTEM
Also known as: benzononantin, benzononatine, tessalon
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Benzonatate is a drug in the Non-narcotic Antitussive class catalogued in DrugCentral. It was first approved by the FDA in 1958. DrugCentral lists 1 molecular target, including SCN5A. Recorded indications include Cough.
- Drug class: Non-narcotic Antitussive.
- Molecular targets: SCN5A (1 listed in DrugCentral).
- Indications: Cough.
- ATC code: R05DB01 (Other cough suppressants).
- Molecular formula: C12H17NO2(C2H4O)7-9.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Cough
Mechanism & targets
| Established pharmacologic class | Non-narcotic Antitussive |
|---|
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Sodium channel protein type 5 subunit alpha | SCN5A | unknown | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1958-02-10 | FDA | — | PFIZER |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
R05DB01 | RESPIRATORY SYSTEM › COUGH AND COLD PREPARATIONS › COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS › Other cough suppressants |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Pneumonia | 298.5 |
| Cough | 215.2 |
| Bronchitis | 193.2 |
| Product dose omission issue | 146.2 |
| COVID-19 | 120.4 |
| Completed suicide | 119.3 |
| Death | 115.9 |
| Conduction disorder | 115.0 |
| Dyspnoea | 97.0 |
| Upper respiratory tract infection | 94.2 |
| Influenza | 90.7 |
| Maternal exposure during pregnancy | 88.2 |
Chemical structure
| Molecular formula | C12H17NO2(C2H4O)7-9 |
|---|---|
| Molecular weight | — |
| CAS number | 104-31-4 |
| InChIKey | — |
| PubChem CID | 7699 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Benzonatate used for?
DrugCentral lists the following indications for Benzonatate: Cough.
How does Benzonatate work?
Its molecular targets in DrugCentral include SCN5A.
When was Benzonatate first approved?
Benzonatate was first approved by the FDA in 1958.
What drug class does Benzonatate belong to?
Benzonatate is in the Non-narcotic Antitussive class.
What is the chemical formula of Benzonatate?
Benzonatate has the molecular formula C12H17NO2(C2H4O)7-9.
Browse: all drugs starting with B · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 326 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1374379 — compound record and bioactivity
- PubChem CID 7699 — chemical identifiers
- DrugBank DB00868 — drug record
- FDA UNII 5P4DHS6ENR — substance identity
- DailyMed: FDA labels for Benzonatate — current prescribing information (label search)
- UniProt Q14524 (SCN5A) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.